ProEncia’s patent-pending products are designed to manage daily exposure to periodontal pathogens, handle pathogen buildup and its harmful effects, manage acute and chronic inflammation, and regulate compromised immune system activities.

ProEncia aims to prevent, protect, repair and resolve periodontal diseases at all stages of severity.

Dual-Purpose Biologically Active Products

ProEncia’s products use a novel formulation to act upon two primary biological mechanisms:

1. Inhibiting critical biological functions in pathogens, deterring their adherence, growth, and the subsequent buildup of plaque, calculus, and caries on dental surfaces. This suppresses the release of microbial virulence factors and toxins, reducing their inflammatory impact on host tissues.

2. Interacting favorably with affected host tissues and the immune system, supporting immune system realignment, tissue repair and restoration, alveolar bone remodeling, and the strengthening of the periodontal foundation.

In Vitro Validation

ProEncia has put its products through rigorous in vitro testing to measure their properties and efficacy via multiple 3rd party laboratory partners as well as ProEncia’s in-house R&D laboratory. These lab results support the hypothesis that ProEncia’s products can inhibit or suppress a variety of major oral pathogens; increase the production and availability of healthy immune and regulatory cell factors; decrease cellular inflammatory factors; and drive cellular healing and regeneration in gum tissue cells.

In Vivo Validation

ProEncia has supplemented its laboratory data with in vivo human data from a small-scale clinical trial. The trial consisted of 10 patients with moderate-to-severe periodontal disease states and a variety of causal and aggravating factors. Trial results showed a significant elimination of bleeding, pain, sensitivity, halitosis, and inflammation across the patient population. A significant improvement in gingival pocket depth was also observed. Results were verified by pre- and post-evaluations in a clinical setting. ProEncia plans to publish a scientific paper in mid-2026 outlining these findings in more detail.